ArticleFrontiers in artificial intelligence2025
Comparative analysis of frequentist, Bayesian, and machine learning models for predicting SARS-CoV-2 PCR positivity.
Article in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prediction of infection status is critical for effective disease management and timely intervention. Traditional diagnostic methods for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are challenged by varying sensitivities and specificities, necessitating the evaluation of advanced statistical approaches. This study evaluated the predictive performance of frequentist logistic regression, Bayesian logistic regression, and a random forest classifier using clinical and demographic predictors to predict PCR positivity. Methodology: A total of 950 participants were analyzed using three modeling approaches. To address class imbalance, the data were balanced using the Synthetic Minority Oversampling Technique (SMOTE) before training the random forest classifier. Predictors include IgG serostatus, travel history (international and domestic), self-reported symptoms (such as loss of smell, fatigue, sore throat), sex, and age. Three models were developed: (1) frequentist logistic regression; (2) Bayesian logistic regression with a moderately informative Normal (mean = 1, SD = 2) prior and a weakly informative Cauchy (0, 2.5) prior; and (3) machine learning (ML) using a random forest classifier. Missing data were minimal (<2%) and handled through imputation, with sensitivity analyses confirming no material impact on model performance. Performance was evaluated using odds ratios, posterior means with credible intervals, and area under the ROC curve (AUC). Results: Of the 950 participants, 74.8% tested positive for SARS-CoV-2. The frequentist logistic regression identified recent international travel (Odds Ratio = 4.8), loss of smell (OR = 2.3), and domestic travel (OR = 1.5) as the strongest predictors of PCR positivity. The Bayesian model yielded similar posterior estimates, confirming the robustness of these associations across prior assumptions. The random forest classifier achieved the highest discriminative performance (AUC = 0.947-0.963). Notably, age and sex were not significant in the regression models but emerged as influential predictors in the random forest model, suggesting possible nonlinear or interaction effects. Conclusion: The machine learning approach (random forest) outperformed the logistic regression models in predictive accuracy. Bayesian regression confirmed the reliability of key predictors and allowed quantification of uncertainty. These findings highlight that simple, routinely collected symptom and exposure data can support rapid, resource-conscious screening for SARS-CoV-2, particularly when laboratory testing capacity is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.